These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 19049823)

  • 1. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
    Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts.
    Caruana G; Cambareri AC; Ashman LK
    Oncogene; 1999 Sep; 18(40):5573-81. PubMed ID: 10523834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
    Montero JC; López-Pérez R; San Miguel JF; Pandiella A
    Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transduction by several KIT juxtamembrane domain mutations.
    Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
    Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
    Ning ZQ; Li J; McGuinness M; Arceci RJ
    Oncogene; 2001 Jul; 20(33):4528-36. PubMed ID: 11494148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
    Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
    J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma.
    Plo I; Lautier D; Casteran N; Dubreuil P; Arock M; Laurent G
    Oncogene; 2001 Oct; 20(46):6752-63. PubMed ID: 11709710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transduction via the stem cell factor receptor/c-Kit.
    Rönnstrand L
    Cell Mol Life Sci; 2004 Oct; 61(19-20):2535-48. PubMed ID: 15526160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
    Chan EC; Bai Y; Bandara G; Simakova O; Brittain E; Scott L; Dyer KD; Klion AD; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
    Exp Hematol; 2013 Oct; 41(10):870-881.e2. PubMed ID: 23743299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
    Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
    Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant.
    Chian R; Young S; Danilkovitch-Miagkova A; Rönnstrand L; Leonard E; Ferrao P; Ashman L; Linnekin D
    Blood; 2001 Sep; 98(5):1365-73. PubMed ID: 11520784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility.
    Blume-Jensen P; Jiang G; Hyman R; Lee KF; O'Gorman S; Hunter T
    Nat Genet; 2000 Feb; 24(2):157-62. PubMed ID: 10655061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
    Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.
    Chaix A; Arcangeli ML; Lopez S; Voisset E; Yang Y; Vita M; Letard S; Audebert S; Finetti P; Birnbaum D; Bertucci F; Aurrand-Lions M; Dubreuil P; De Sepulveda P
    Oncogene; 2014 Feb; 33(7):872-81. PubMed ID: 23416972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
    Lindblad O; Kazi JU; Rönnstrand L; Sun J
    Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferation and differentiation of spermatogonial stem cells in the w/wv mutant mouse testis.
    Ohta H; Tohda A; Nishimune Y
    Biol Reprod; 2003 Dec; 69(6):1815-21. PubMed ID: 12890724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.